These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 17429318)
1. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696 [TBL] [Abstract][Full Text] [Related]
3. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model. Campbell HM; Boardman KD; Dodd MA; Raisch DW Ann Pharmacother; 2007 Jul; 41(7):1101-10. PubMed ID: 17609233 [TBL] [Abstract][Full Text] [Related]
5. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes. Swislocki AL; Siegel D Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. Stafylas PC; Sarafidis PA; Lasaridis AN; Tsakni E; Niakas DA; Dombros NV; Grekas DM; Bakris GL J Nephrol; 2007; 20(6):703-15. PubMed ID: 18046673 [TBL] [Abstract][Full Text] [Related]
8. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Pereira TV; Nunes AC; Rudnicki M; Magistroni R; Albertazzi A; Pereira AC; Krieger JE Nephrol Dial Transplant; 2006 Nov; 21(11):3155-63. PubMed ID: 16935894 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of benazepril in chronic renal insufficiency. van Hout BA; Simeon GP; McDonnell J; Mann JF Kidney Int Suppl; 1997 Dec; 63():S159-62. PubMed ID: 9407447 [TBL] [Abstract][Full Text] [Related]
10. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients. Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561 [TBL] [Abstract][Full Text] [Related]
11. ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease. Sakka Y; Babazono T; Sato A; Ujihara N; Iwamoto Y Diabetes Res Clin Pract; 2004 Apr; 64(1):41-9. PubMed ID: 15036826 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Adarkwah CC; Gandjour A Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782 [TBL] [Abstract][Full Text] [Related]
13. [The significance of angiotensin-converting enzyme inhibitors genotype for ACEi response in patients with chronic allograft nephropathy]. Savin M; Petronić V Srp Arh Celok Lek; 2005; 133(3-4):194-8. PubMed ID: 16206711 [TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of sevelamer in patients with end-stage renal disease. Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Brugts JJ; Danser AH; de Maat MP; den Uil CA; Boersma E; Ferrari R; Simoons ML Curr Opin Cardiol; 2008 Jul; 23(4):296-301. PubMed ID: 18520711 [TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients. Akman B; Tarhan C; Arat Z; Sezer S; Ozdemir FN Ren Fail; 2009; 31(3):196-200. PubMed ID: 19288324 [TBL] [Abstract][Full Text] [Related]
19. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Smith DG; Cerulli A; Frech FH Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995 [TBL] [Abstract][Full Text] [Related]
20. Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade. Moon JY; Jeong KH; Paik SS; Han JJ; Lee SH; Lee TW; Ihm CG; Kim MJ; Chung JH Nephron Clin Pract; 2009; 111(2):c110-6. PubMed ID: 19142023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]